董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| August J. Troendle | 男 | President, Chief Executive Officer and Chairman of the Board | 64 | 113.21万美元 | 未持股 | 2021-03-30 |
| Robert O. Kraft | 男 | Director | 50 | 14.50万美元 | 未持股 | 2021-03-30 |
| Brian T. Carley | 男 | Director | 67 | 15.00万美元 | 未持股 | 2021-03-30 |
| Fred B. Davenport, Jr. | 男 | Lead Director | 69 | 14.50万美元 | 未持股 | 2021-03-30 |
| Cornelius P. McCarthy III | 男 | Director | 61 | 13.75万美元 | 未持股 | 2021-03-30 |
| Ashley M. Keating | 女 | Director | 39 | 13.00万美元 | 未持股 | 2021-03-30 |
| Thomas C. King | -- | Director | 63 | 13.00万美元 | 未持股 | 2021-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| August J. Troendle | 男 | President, Chief Executive Officer and Chairman of the Board | 64 | 113.21万美元 | 未持股 | 2021-03-30 |
| Jesse J. Geiger | 男 | Chief Financial Officer and Chief Operating Officer, Laboratory Operations | 46 | 67.82万美元 | 未持股 | 2021-03-30 |
| Susan E. Burwig | 女 | Executive Vice President, Operations | 58 | 75.02万美元 | 未持股 | 2021-03-30 |
| Stephen P. Ewald | 男 | General Counsel and Corporate Secretary | 51 | 58.76万美元 | 未持股 | 2021-03-30 |
董事简历
中英对照 | 中文 | 英文- August J. Troendle
-
August J. Troendle获得医学博士学位，他从2011年3月开始一直担任我司董事会董事。Troendle博士从公司于1992年成立开始一直担任Medpace, Inc.的首席执行官，这是一家临床研究机构。在这之前，Troendle博士在山德士公司（Sandoz Novartis）任职，他在该公司负责调脂药的临床开发。在这之前，从2009年到2010年，他还担任氙制药公司（Xenon Pharmaceuticals Inc.）的董事。Troendle博士在马里兰大学医学院（University of Maryland School of Medicine）获得医学博士学位。
August J. Troendle, M.D. has been the President, Chief Executive Officer and Chairman of the Board of Medpace since he founded the Company in July 1992. Before founding Medpace, Mr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz Novartis, where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987 Mr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Mr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018 as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008 as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. - August J. Troendle获得医学博士学位，他从2011年3月开始一直担任我司董事会董事。Troendle博士从公司于1992年成立开始一直担任Medpace, Inc.的首席执行官，这是一家临床研究机构。在这之前，Troendle博士在山德士公司（Sandoz Novartis）任职，他在该公司负责调脂药的临床开发。在这之前，从2009年到2010年，他还担任氙制药公司（Xenon Pharmaceuticals Inc.）的董事。Troendle博士在马里兰大学医学院（University of Maryland School of Medicine）获得医学博士学位。
- August J. Troendle, M.D. has been the President, Chief Executive Officer and Chairman of the Board of Medpace since he founded the Company in July 1992. Before founding Medpace, Mr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz Novartis, where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987 Mr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Mr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018 as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008 as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015.
- Robert O. Kraft
-
Robert O. Kraft，2016年7月1日起成为董事会的成员。2015年8月，Kraft先生担任Omnicare, Inc.，CVS长期护理业务总裁和CVS Health Corporation执行副总裁。2012年9月-2015年8月，Kraft先生担任Omnicare, Inc.高级副总裁和首席财务官；2010年11月-2012年9月担任Omnicare, Inc.财务高级副总裁。加入Omnicare, Inc.之前，Kraft先生是 PricewaterhouseCoopers LLP的一名审计合伙人，在PricewaterhouseCoopers LLP工作了18年的时间。Kraft先生获得Dayton大学会计学士学位。
Robert O. Kraft has served as the Chief Financial Officer and Treasurer of The Hillman Companies, Inc. and The Hillman Group since November 2017. Mr. Kraft served as the Executive Vice President of CVS Health Corporation and the President of Omnicare, Inc., CVS's long-term care business, from August 2015 to September 2017. From September 2012 to August 2015 Mr. Kraft served as Senior Vice President and Chief Financial Officer of Omnicare, Inc., and from November 2010 to September 2012 he served as Senior Vice President, Finance of Omnicare, Inc. Before joining Omnicare, Inc., Mr. Kraft was an audit partner at PricewaterhouseCoopers LLP, where he worked for 18 years. - Robert O. Kraft，2016年7月1日起成为董事会的成员。2015年8月，Kraft先生担任Omnicare, Inc.，CVS长期护理业务总裁和CVS Health Corporation执行副总裁。2012年9月-2015年8月，Kraft先生担任Omnicare, Inc.高级副总裁和首席财务官；2010年11月-2012年9月担任Omnicare, Inc.财务高级副总裁。加入Omnicare, Inc.之前，Kraft先生是 PricewaterhouseCoopers LLP的一名审计合伙人，在PricewaterhouseCoopers LLP工作了18年的时间。Kraft先生获得Dayton大学会计学士学位。
- Robert O. Kraft has served as the Chief Financial Officer and Treasurer of The Hillman Companies, Inc. and The Hillman Group since November 2017. Mr. Kraft served as the Executive Vice President of CVS Health Corporation and the President of Omnicare, Inc., CVS's long-term care business, from August 2015 to September 2017. From September 2012 to August 2015 Mr. Kraft served as Senior Vice President and Chief Financial Officer of Omnicare, Inc., and from November 2010 to September 2012 he served as Senior Vice President, Finance of Omnicare, Inc. Before joining Omnicare, Inc., Mr. Kraft was an audit partner at PricewaterhouseCoopers LLP, where he worked for 18 years.
- Brian T. Carley
-
Brian T. Carley，2016年7月1日以来，他一直担任我们董事会的成员。他目前是Clubessential, LLC（私有软件服务SaaS软件公司，提供成员参与软件）的高级副总裁兼首席财务官。他此前曾担任 the Cincinnati USA Regional Chamber的总裁和首席执行官（从2014年到2015年）。2002年至2014年，他曾任职Deloitte & Touche LLP，在那里他曾担任区域和职员审计部门主管，以及审计合伙人。加入Deloitte & Touche LLP之前，他曾任职Arthur Andersen LLP（1976年至2002年）。他曾担任职员管理合伙人、审计合伙人。
Brian T. Carley is currently the Senior Vice President and Chief Financial Officer of Clubessential Holdings, LLC, a privately held Software as a Service SaaS holding company providing member engagement, club management and athletics software. He previously served as President and Chief Executive Officer of the Cincinnati USA Regional Chamber from 2014 to 2015. From 2002 to 2014 Mr. Carley worked at Deloitte & Touche LLP, where he served as regional and office audit division head and audit partner. Before joining Deloitte & Touche LLP, Mr. Carley was employed by Arthur Andersen LLP from 1976 to 2002. There, he served as office managing partner and audit partner. Mr. Carley also has extensive experience serving as a director for a diverse group of companies, including as a director of Assurex Health, Inc. from 2015 until its sale in August 2016 and as a director and officer of numerous civic and charitable organizations. Mr. Carley currently sits on the board of directors of the following private companies or civic and charitable organizations: Clubessential, LLC, ClubReady, LLC, PrestoSports, LLC, RecTrac, LLC, (formerly Vermont Systems, Inc.), Golf Compete, Inc. (dba foreUP), TriHealth, Inc. and Cincinnati Works. - Brian T. Carley，2016年7月1日以来，他一直担任我们董事会的成员。他目前是Clubessential, LLC（私有软件服务SaaS软件公司，提供成员参与软件）的高级副总裁兼首席财务官。他此前曾担任 the Cincinnati USA Regional Chamber的总裁和首席执行官（从2014年到2015年）。2002年至2014年，他曾任职Deloitte & Touche LLP，在那里他曾担任区域和职员审计部门主管，以及审计合伙人。加入Deloitte & Touche LLP之前，他曾任职Arthur Andersen LLP（1976年至2002年）。他曾担任职员管理合伙人、审计合伙人。
- Brian T. Carley is currently the Senior Vice President and Chief Financial Officer of Clubessential Holdings, LLC, a privately held Software as a Service SaaS holding company providing member engagement, club management and athletics software. He previously served as President and Chief Executive Officer of the Cincinnati USA Regional Chamber from 2014 to 2015. From 2002 to 2014 Mr. Carley worked at Deloitte & Touche LLP, where he served as regional and office audit division head and audit partner. Before joining Deloitte & Touche LLP, Mr. Carley was employed by Arthur Andersen LLP from 1976 to 2002. There, he served as office managing partner and audit partner. Mr. Carley also has extensive experience serving as a director for a diverse group of companies, including as a director of Assurex Health, Inc. from 2015 until its sale in August 2016 and as a director and officer of numerous civic and charitable organizations. Mr. Carley currently sits on the board of directors of the following private companies or civic and charitable organizations: Clubessential, LLC, ClubReady, LLC, PrestoSports, LLC, RecTrac, LLC, (formerly Vermont Systems, Inc.), Golf Compete, Inc. (dba foreUP), TriHealth, Inc. and Cincinnati Works.
- Fred B. Davenport, Jr.
-
Fred B.Davenport，Jr.是Murchison，Taylor&Gibson，PLLC律师事务所的合伙人，专注于并购，一般公司代表和遗产规划。此前，他曾担任Pharmaceutical ProductDevelopment，Inc.的总裁（从2002年到2006年）。从2001年到2002年，Davenport先生担任PPD的执行副总裁，从1996年到2001年，他担任PPD的总法律顾问。在加入PPD之前，从1977年到1980年，Davenport先生在Murchison，Taylor&Gibson，PLLC担任合伙人，从1981年到1996年担任合伙人，其中包括从1991年到1995年担任管理合伙人。Davenport先生还曾在卡梅伦商学院担任终身教授。从2015年到2016年3月，Davenport先生担任Clinipace Worldwide的董事，从2009年到2011年，他担任Medex Global Group，Inc.的董事。此外，从2007年到2013年，Davenport先生担任公司前身实体的董事。Davenport先生还在许多社区和非营利组织董事会任职。
Fred B. Davenport, Jr. is a partner at the law firm of Murchison, Taylor & Gibson, PLLC and focuses his practice on mergers and acquisitions, general corporate representation and estate planning. He previously served as President of Pharmaceutical Product Development, Inc. "PPD" from 2002 to 2006. From 2001 to 2002 Mr. Davenport was Executive Vice President of PPD and from 1996 to 2001 he was General Counsel of PPD. Prior to joining PPD, Mr. Davenport practiced at Murchison, Taylor & Gibson, PLLC as an associate from 1977 to 1980 and as a partner from 1981 to 1996 which included acting as the managing partner from 1991 to 1995. Mr. Davenport has also served on the faculty of the Cameron School of Business as a tenured professor. From 2015 to March 2016 Mr. Davenport was a Director of Clinipace Worldwide and from 2009 to 2011 he was a Director of Medex Global Group, Inc. Additionally, Mr. Davenport was a Director of predecessor entities of the Company from 2007 to 2013. Mr. Davenport has also served on numerous community and non-profit boards. - Fred B.Davenport，Jr.是Murchison，Taylor&Gibson，PLLC律师事务所的合伙人，专注于并购，一般公司代表和遗产规划。此前，他曾担任Pharmaceutical ProductDevelopment，Inc.的总裁（从2002年到2006年）。从2001年到2002年，Davenport先生担任PPD的执行副总裁，从1996年到2001年，他担任PPD的总法律顾问。在加入PPD之前，从1977年到1980年，Davenport先生在Murchison，Taylor&Gibson，PLLC担任合伙人，从1981年到1996年担任合伙人，其中包括从1991年到1995年担任管理合伙人。Davenport先生还曾在卡梅伦商学院担任终身教授。从2015年到2016年3月，Davenport先生担任Clinipace Worldwide的董事，从2009年到2011年，他担任Medex Global Group，Inc.的董事。此外，从2007年到2013年，Davenport先生担任公司前身实体的董事。Davenport先生还在许多社区和非营利组织董事会任职。
- Fred B. Davenport, Jr. is a partner at the law firm of Murchison, Taylor & Gibson, PLLC and focuses his practice on mergers and acquisitions, general corporate representation and estate planning. He previously served as President of Pharmaceutical Product Development, Inc. "PPD" from 2002 to 2006. From 2001 to 2002 Mr. Davenport was Executive Vice President of PPD and from 1996 to 2001 he was General Counsel of PPD. Prior to joining PPD, Mr. Davenport practiced at Murchison, Taylor & Gibson, PLLC as an associate from 1977 to 1980 and as a partner from 1981 to 1996 which included acting as the managing partner from 1991 to 1995. Mr. Davenport has also served on the faculty of the Cameron School of Business as a tenured professor. From 2015 to March 2016 Mr. Davenport was a Director of Clinipace Worldwide and from 2009 to 2011 he was a Director of Medex Global Group, Inc. Additionally, Mr. Davenport was a Director of predecessor entities of the Company from 2007 to 2013. Mr. Davenport has also served on numerous community and non-profit boards.
- Cornelius P. McCarthy III
-
Cornelius P.McCarthy III自2003年以来担任Fairmount Partners的总经理兼首席执行官，主要专注于医疗保健和制药外包服务。在创立Fairmount Partners之前，从1997年到2003年，McCarthy先生担任PMG/Investec的副总裁，董事总经理兼美国投资银行业务主管。在1997年之前，McCarthy先生担任过许多法律和投资银行职务。McCarthy先生目前是Atlantic Research Services，LLC和NMS Laboratories，Inc.的董事。此外，McCarthy先生于2016年12月至2019年11月被出售期间担任Cambridge Biomedical，Inc.的董事，并于2006年至2013年担任公司前身的董事。
Cornelius P. McCarthy III has served as the Managing Director and CEO of Fairmount Partners since 2003 and focuses primarily on healthcare and pharmaceutical outsourced services. Prior to founding Fairmount Partners, Mr. McCarthy was Vice President, Managing Director and Head of US Investment Banking at PMG/Investec from 1997 to 2003. Prior to 1997 Mr. McCarthy held a number of legal and investment banking roles. Mr. McCarthy is currently a Director of Atlantic Research Services, LLC and NMS Laboratories, Inc. Additionally, Mr. McCarthy was a Director of Cambridge Biomedical, Inc. from December 2016 until its sale in November 2019 and from 2006 to 2013 he was a Director of predecessor entities of the Company. - Cornelius P.McCarthy III自2003年以来担任Fairmount Partners的总经理兼首席执行官，主要专注于医疗保健和制药外包服务。在创立Fairmount Partners之前，从1997年到2003年，McCarthy先生担任PMG/Investec的副总裁，董事总经理兼美国投资银行业务主管。在1997年之前，McCarthy先生担任过许多法律和投资银行职务。McCarthy先生目前是Atlantic Research Services，LLC和NMS Laboratories，Inc.的董事。此外，McCarthy先生于2016年12月至2019年11月被出售期间担任Cambridge Biomedical，Inc.的董事，并于2006年至2013年担任公司前身的董事。
- Cornelius P. McCarthy III has served as the Managing Director and CEO of Fairmount Partners since 2003 and focuses primarily on healthcare and pharmaceutical outsourced services. Prior to founding Fairmount Partners, Mr. McCarthy was Vice President, Managing Director and Head of US Investment Banking at PMG/Investec from 1997 to 2003. Prior to 1997 Mr. McCarthy held a number of legal and investment banking roles. Mr. McCarthy is currently a Director of Atlantic Research Services, LLC and NMS Laboratories, Inc. Additionally, Mr. McCarthy was a Director of Cambridge Biomedical, Inc. from December 2016 until its sale in November 2019 and from 2006 to 2013 he was a Director of predecessor entities of the Company.
- Ashley M. Keating
-
Ashley M.Keating目前是CincyTech的首席财务官，CincyTech是中西部最活跃的种子阶段投资者之一，专注于为俄亥俄州西南部的人类健康和技术公司提供启动资金和指导。从2005年到2016年4月，她曾任职PricewaterhouseCoopers PwC，在那里她专注于金融、运营、业务领导和并购。她的职业生涯始于任职PwC’；的辛辛那提办事处的审计服务，后来转到PwC’；的交易服务实践，在纽约和伦敦办事处。
Ashley M. Keating is currently the Chief Financial Officer of CincyTech, one of the most active seed-stage investors in the Midwest focused on providing startup capital and guidance to human health and technology companies primarily in Southwest Ohio. From 2005 to April 2016 Ms. Keating worked at PricewaterhouseCoopers PwC where she focused on finance, operations, business leadership and mergers and acquisitions. She began her career in audit services at PwC’s Cincinnati office and later transferred to PwC’s transaction services practice in the New York and London offices. - Ashley M.Keating目前是CincyTech的首席财务官，CincyTech是中西部最活跃的种子阶段投资者之一，专注于为俄亥俄州西南部的人类健康和技术公司提供启动资金和指导。从2005年到2016年4月，她曾任职PricewaterhouseCoopers PwC，在那里她专注于金融、运营、业务领导和并购。她的职业生涯始于任职PwC’；的辛辛那提办事处的审计服务，后来转到PwC’；的交易服务实践，在纽约和伦敦办事处。
- Ashley M. Keating is currently the Chief Financial Officer of CincyTech, one of the most active seed-stage investors in the Midwest focused on providing startup capital and guidance to human health and technology companies primarily in Southwest Ohio. From 2005 to April 2016 Ms. Keating worked at PricewaterhouseCoopers PwC where she focused on finance, operations, business leadership and mergers and acquisitions. She began her career in audit services at PwC’s Cincinnati office and later transferred to PwC’s transaction services practice in the New York and London offices.
- Thomas C. King
-
Thomas C.King是一名医生和董事会认证的病理学家，拥有分子生物学博士学位，并在医院，学术和企业环境中担任实验室主任有丰富的经验。目前，金博士是Immunovia，Inc.的医学总监，也是新泽西州立大学罗格斯大学卫生专业学院的副教授。从2013年到2017年，金博士担任马萨诸塞州伍斯特市圣文森特医院的病理学和实验室医学主任。从2009年到2013年，King博士是位于罗德岛普罗维登斯的University Pathologists，LLC的病理学和实验室医学的合伙人兼医学总监，从2007年到2008年，担任罗德岛普罗维登斯大学医疗集团的病理学和实验室医学的医学总监。从2002年到2003年，King博士是Millennium Pharmaceuticals分子病理学的高级主管。此外，King博士在学术界担任过各种职务，包括波士顿大学医学院，布朗大学医学院，康涅狄格大学医学院和华盛顿大学医学中心。从2004年到2011年，King博士担任公司前身实体的董事兼公司治理委员会主席。
Thomas C. King is a physician and a board certified Pathologist with a Ph.D. in Molecular Biology and extensive experience as a laboratory director in hospital, academic and corporate settings. Currently Dr. King is the Medical Director at Immunovia, Inc. and an Adjunct Associate Professor in the School of Health Professions at Rutgers, The State University of New Jersey. From 2013 to 2017 Dr. King was the Chief of Pathology and Laboratory Medicine at St. Vincent Hospital in Worcester, Massachusetts. Dr. King was a Partner and Medical Director of Pathology and Laboratory Medicine at University Pathologists, LLC in Providence, Rhode Island from 2009 to 2013 and the Medical Director of Pathology and Laboratory Medicine at the University Medical Group in Providence, Rhode Island from 2007 to 2008. From 2002 to 2003 Dr. King was the Senior Director of Molecular Pathology at Millennium Pharmaceuticals. Additionally, Dr. King has held various positions in academia including at Boston University School of Medicine, Brown University School of Medicine, the University of Connecticut School of Medicine and Washington University Medical Center. Dr. King was a Director and Chair of the Corporate Governance Committee of predecessor entities of the Company from 2004 to 2011. - Thomas C.King是一名医生和董事会认证的病理学家，拥有分子生物学博士学位，并在医院，学术和企业环境中担任实验室主任有丰富的经验。目前，金博士是Immunovia，Inc.的医学总监，也是新泽西州立大学罗格斯大学卫生专业学院的副教授。从2013年到2017年，金博士担任马萨诸塞州伍斯特市圣文森特医院的病理学和实验室医学主任。从2009年到2013年，King博士是位于罗德岛普罗维登斯的University Pathologists，LLC的病理学和实验室医学的合伙人兼医学总监，从2007年到2008年，担任罗德岛普罗维登斯大学医疗集团的病理学和实验室医学的医学总监。从2002年到2003年，King博士是Millennium Pharmaceuticals分子病理学的高级主管。此外，King博士在学术界担任过各种职务，包括波士顿大学医学院，布朗大学医学院，康涅狄格大学医学院和华盛顿大学医学中心。从2004年到2011年，King博士担任公司前身实体的董事兼公司治理委员会主席。
- Thomas C. King is a physician and a board certified Pathologist with a Ph.D. in Molecular Biology and extensive experience as a laboratory director in hospital, academic and corporate settings. Currently Dr. King is the Medical Director at Immunovia, Inc. and an Adjunct Associate Professor in the School of Health Professions at Rutgers, The State University of New Jersey. From 2013 to 2017 Dr. King was the Chief of Pathology and Laboratory Medicine at St. Vincent Hospital in Worcester, Massachusetts. Dr. King was a Partner and Medical Director of Pathology and Laboratory Medicine at University Pathologists, LLC in Providence, Rhode Island from 2009 to 2013 and the Medical Director of Pathology and Laboratory Medicine at the University Medical Group in Providence, Rhode Island from 2007 to 2008. From 2002 to 2003 Dr. King was the Senior Director of Molecular Pathology at Millennium Pharmaceuticals. Additionally, Dr. King has held various positions in academia including at Boston University School of Medicine, Brown University School of Medicine, the University of Connecticut School of Medicine and Washington University Medical Center. Dr. King was a Director and Chair of the Corporate Governance Committee of predecessor entities of the Company from 2004 to 2011.
高管简历
中英对照 | 中文 | 英文- August J. Troendle
August J. Troendle获得医学博士学位，他从2011年3月开始一直担任我司董事会董事。Troendle博士从公司于1992年成立开始一直担任Medpace, Inc.的首席执行官，这是一家临床研究机构。在这之前，Troendle博士在山德士公司（Sandoz Novartis）任职，他在该公司负责调脂药的临床开发。在这之前，从2009年到2010年，他还担任氙制药公司（Xenon Pharmaceuticals Inc.）的董事。Troendle博士在马里兰大学医学院（University of Maryland School of Medicine）获得医学博士学位。
August J. Troendle, M.D. has been the President, Chief Executive Officer and Chairman of the Board of Medpace since he founded the Company in July 1992. Before founding Medpace, Mr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz Novartis, where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987 Mr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Mr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018 as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008 as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015.- August J. Troendle获得医学博士学位，他从2011年3月开始一直担任我司董事会董事。Troendle博士从公司于1992年成立开始一直担任Medpace, Inc.的首席执行官，这是一家临床研究机构。在这之前，Troendle博士在山德士公司（Sandoz Novartis）任职，他在该公司负责调脂药的临床开发。在这之前，从2009年到2010年，他还担任氙制药公司（Xenon Pharmaceuticals Inc.）的董事。Troendle博士在马里兰大学医学院（University of Maryland School of Medicine）获得医学博士学位。
- August J. Troendle, M.D. has been the President, Chief Executive Officer and Chairman of the Board of Medpace since he founded the Company in July 1992. Before founding Medpace, Mr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz Novartis, where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987 Mr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Mr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018 as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008 as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015.
- Jesse J. Geiger
Jesse J. Geiger，2007年10月加入Medpace担任财务总监，2011年3月，他被任命为首席财务官。2014年11月，Geiger先生成为实验室操作首席运营官。加入Medpace之前，2004年到2007年，Geiger先生工作于SENCORP担任财务总监和财务规划和分析经理。SENCORP之前，2002年到2004年，Geiger先生担任Cincinnati Bell 资本市场主管。Geiger先生在Arthur Andersen LLP开始他的审计职业生涯。Geiger先生有几家私人公司担任主管，包括作为Symplmed Pharmaceuticals, LLC董事、2013年以来；2016年以来LIB Therapeutics, LLC董事；自2016年以来CinRx Pharma, LLC董事。Geiger先生收到了辛辛那提大学工商管理会计方向学士学位，他也是一个注册会计师。
Jesse J. Geiger joined Medpace in October 2007 as Corporate Controller, and he was appointed Chief Financial Officer in March 2011. Mr. Geiger became Chief Operating Officer, Laboratory Operations in November 2014. Prior to joining Medpace, Mr. Geiger worked for SENCORP from 2004 to 2007 as the Corporate Controller and Manager of Financial Planning and Analysis. Prior to SENCORP, Mr. Geiger served as the Director of Capital Markets for Cincinnati Bell from 2002 to 2004. Mr. Geiger started his career in the audit practice at Arthur Andersen LLP. Mr. Geiger has served as a director for several private companies, including as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Geiger received his Bachelor of Business Administration in Accounting from the University of Cincinnati and is a Certified Public Accountant.- Jesse J. Geiger，2007年10月加入Medpace担任财务总监，2011年3月，他被任命为首席财务官。2014年11月，Geiger先生成为实验室操作首席运营官。加入Medpace之前，2004年到2007年，Geiger先生工作于SENCORP担任财务总监和财务规划和分析经理。SENCORP之前，2002年到2004年，Geiger先生担任Cincinnati Bell 资本市场主管。Geiger先生在Arthur Andersen LLP开始他的审计职业生涯。Geiger先生有几家私人公司担任主管，包括作为Symplmed Pharmaceuticals, LLC董事、2013年以来；2016年以来LIB Therapeutics, LLC董事；自2016年以来CinRx Pharma, LLC董事。Geiger先生收到了辛辛那提大学工商管理会计方向学士学位，他也是一个注册会计师。
- Jesse J. Geiger joined Medpace in October 2007 as Corporate Controller, and he was appointed Chief Financial Officer in March 2011. Mr. Geiger became Chief Operating Officer, Laboratory Operations in November 2014. Prior to joining Medpace, Mr. Geiger worked for SENCORP from 2004 to 2007 as the Corporate Controller and Manager of Financial Planning and Analysis. Prior to SENCORP, Mr. Geiger served as the Director of Capital Markets for Cincinnati Bell from 2002 to 2004. Mr. Geiger started his career in the audit practice at Arthur Andersen LLP. Mr. Geiger has served as a director for several private companies, including as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Geiger received his Bachelor of Business Administration in Accounting from the University of Cincinnati and is a Certified Public Accountant.
- Susan E. Burwig
Susan E. Burwig，她于1993年8月加入Medpace公司，也曾担任临床操作部门的多种关键领导职务。从2003年2月到2015年5月，她曾担任高级副总裁，负责临床操作、监督临床试验管理、临床监测、启动（包括可行性，以及新业务的建议）。她于2015年6月被任命为高级运营副总裁。加入Medpace公司之前，她曾担任一些临床职务，包括领导the University of Cincinnati的心力衰竭的临床研究。她持有Kent State University的护理学士以及体育管理硕士学位。
Susan E. Burwig joined Medpace in August 1993 and has served in various key leadership roles within the Clinical Operations department. From February 2003 to May 2015 Ms. Burwig served as Senior Vice President, Clinical Operations, overseeing clinical trial management, clinical monitoring, start-up, including feasibility, and new business proposals. In June 2015 Ms. Burwig was appointed Senior Vice President, Operations, and in January 2017 she was named as Executive Vice President, Operations. Prior to joining Medpace, Ms. Burwig held several clinical roles, including leading heart failure clinical research studies at the University of Cincinnati. Ms. Burwig received her Bachelor of Science in Nursing as well as an MA in Sports Administration from Kent State University.- Susan E. Burwig，她于1993年8月加入Medpace公司，也曾担任临床操作部门的多种关键领导职务。从2003年2月到2015年5月，她曾担任高级副总裁，负责临床操作、监督临床试验管理、临床监测、启动（包括可行性，以及新业务的建议）。她于2015年6月被任命为高级运营副总裁。加入Medpace公司之前，她曾担任一些临床职务，包括领导the University of Cincinnati的心力衰竭的临床研究。她持有Kent State University的护理学士以及体育管理硕士学位。
- Susan E. Burwig joined Medpace in August 1993 and has served in various key leadership roles within the Clinical Operations department. From February 2003 to May 2015 Ms. Burwig served as Senior Vice President, Clinical Operations, overseeing clinical trial management, clinical monitoring, start-up, including feasibility, and new business proposals. In June 2015 Ms. Burwig was appointed Senior Vice President, Operations, and in January 2017 she was named as Executive Vice President, Operations. Prior to joining Medpace, Ms. Burwig held several clinical roles, including leading heart failure clinical research studies at the University of Cincinnati. Ms. Burwig received her Bachelor of Science in Nursing as well as an MA in Sports Administration from Kent State University.
- Stephen P. Ewald
Stephen P. Ewald，他于2012年6月加入Medpace公司，担任法律总顾问兼公司秘书。加入Medpace公司之前，他曾担任Brevet Capital Management公司的董事总经理兼首席法务官（2011年5月至2012年6月）。从2009年5月到2011年5月，他曾担任Cantor Fitzgerald Securities/Cantor Fitzgerald & Co。的董事总经理兼助理总法律顾问。他也曾任职Bank of America公司（从1999年到2009年），也曾担任the Principal Capital Group（Bank of America Securities的自营投资集团）的法律部门和集团全球市场的多种职务，包括董事总经理兼首席运营官他也曾担任一些私人公司的董事，包括担任Symplmed Pharmaceuticals, LLC的董事（2013年以来）、LIB Therapeutics, LLC的董事（2016年以来）、CinRx Pharma, LLC的董事（2016年以来）。他持有the University of Cincinnati的政治科学学士学位，以及the University of Cincinnati College of Law的法学博士学位。
Stephen P. Ewald joined Medpace as General Counsel and Corporate Secretary in June 2012. Mr. Ewald has also led the Human Resources department and other administrative functions since the third quarter of 2017. Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011 he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009 serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities. Mr. Ewald has served as director for several private companies, including as a director and chairman of the board of Mercy Health Foundation Board Cincinnati since 2015 and 2018 respectively, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.- Stephen P. Ewald，他于2012年6月加入Medpace公司，担任法律总顾问兼公司秘书。加入Medpace公司之前，他曾担任Brevet Capital Management公司的董事总经理兼首席法务官（2011年5月至2012年6月）。从2009年5月到2011年5月，他曾担任Cantor Fitzgerald Securities/Cantor Fitzgerald & Co。的董事总经理兼助理总法律顾问。他也曾任职Bank of America公司（从1999年到2009年），也曾担任the Principal Capital Group（Bank of America Securities的自营投资集团）的法律部门和集团全球市场的多种职务，包括董事总经理兼首席运营官他也曾担任一些私人公司的董事，包括担任Symplmed Pharmaceuticals, LLC的董事（2013年以来）、LIB Therapeutics, LLC的董事（2016年以来）、CinRx Pharma, LLC的董事（2016年以来）。他持有the University of Cincinnati的政治科学学士学位，以及the University of Cincinnati College of Law的法学博士学位。
- Stephen P. Ewald joined Medpace as General Counsel and Corporate Secretary in June 2012. Mr. Ewald has also led the Human Resources department and other administrative functions since the third quarter of 2017. Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011 he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009 serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities. Mr. Ewald has served as director for several private companies, including as a director and chairman of the board of Mercy Health Foundation Board Cincinnati since 2015 and 2018 respectively, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.